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Patients with a diagnosis of cancer are purported to have poor outcomes from COVID-19. However, cancer is a 41 
heterogeneous group of diseases encompassing a wide spectrum of primary tumour subtypes and there have been 42 
no studies evaluating risk from COVID-19 according to cancer subtype and general demographics in the cancer 43 
patient population 44 
 45 
Methods 46 
A comparison of cancer patients enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) and a 47 
parallel non-COVID-19 UK cancer control population cohort was performed, analysing the effect of tumour subtype 48 
and patient demographics (age and sex) on the risk and the trajectory of COVID-19.  49 
   50 
Findings 51 
In 1,044 patients with COVID-19 enrolled into the UKCCMP we observe that tumour features as well as patient 52 
demographics impact on viral susceptibility and COVID-19 phenotype. SARS-CoV-2 susceptibility is increased in 53 
patients with haematological malignancies (leukaemia/lymphoma/myeloma), and these patients run a more severe 54 
COVID-19 trajectory (OR 1.57, 95% CI 1.15-2.15; p=0.004) and require more intensive clinical support.  Case 55 
fatality rate following COVID-19 in patients with leukaemia is increased compared to other cancer types, even 56 
considering other risk factors (OR 2.25, 95% CI [1.13 to 4.57]; p=0.023). Gender and age are the overriding risk 57 
factors for SARS-CoV-2 infection and severity of COVID-19 for most cancer patients, as they are for the general 58 
population.   59 
 60 
Interpretation 61 
Cancer patients with different tumours have differing SARS-CoV-2 susceptibility and COVID-19 phenotypes. We 62 
have generated individualised risk tables for cancer patients taking into account age/sex and tumour subtype. This 63 
will be useful for physicians to have a more informed risk-benefit discussion to explain COVID-19 risk to their cancer 64 





The disease course of individuals contracting SARS-CoV-2 infection is phenotypically diverse. Many patients suffer 68 
only mild symptoms and it is becoming increasingly apparent from antibody data, that others suffer no symptoms 69 
at all but can actively carry and transmit the infection. However, at the other end of the spectrum, some individuals 70 
develop very severe symptoms and can follow an extreme phenotype with the development of respiratory failure, 71 
cytokine release syndrome and multi-organ failure. Subgroups of COVID-19 patients have been identified who 72 
appear to be at increased risk of extreme morbidity and mortality, including patients of advancing age, male gender 73 
(versus female) and those with co-morbidities such as hypertension, chronic lung disease, diabetes and cancer 74 
(1).  75 
 76 
Since COVID-19 started to spread across the globe in early 2020, patients with a diagnosis of cancer were 77 
designated as a particularly vulnerable subgroup of the population. Cancer patients have been reported to be not 78 
only at increased risk of contracting SARS-CoV-2 infections, but also of running a more severe disease course, 79 
with a higher proportion requiring higher levels of intensive care, having a more rapidly evolving disease, and with 80 
increased risk of death. (2) (3) (4)  However, as every subspecialised oncologist knows, the term ‘cancer’ 81 
encompasses a myriad of disease, with a diverse array of primary tumour subtype and stages, affecting a 82 
heterogeneous group of patients of all ages, and which result in very different cancer prognoses and outcomes. 83 
Therefore, labelling all cancer patients as ‘COVID-19 vulnerable’ is probably neither reasonable nor informative.  84 
 85 
As a consequence of generic advice given to ‘COVID-19 vulnerable’ members of the population, cancer patients 86 
(of any age, gender, tumour subtype and stage) have been labelled as high risk from COVID-19 and this has led 87 
to sweeping changes in cancer management for all cancer types over the last few months, including abbreviation 88 
of radiotherapy, switching from IV to oral chemotherapy regimens, and the avoidance of immunotherapy. (5) (6) 89 
(7) (8) These changes, perhaps reasonably in an acute pandemic situation, were instigated with very little evidence 90 
to support them. And due to lack of evolving evidence, there has been little attempt to define the individualised risk 91 
for a given patient, taking into account their primary tumour subtype, age and gender. 92 
 93 
We report here, from the UK Coronavirus Cancer Monitoring Project (9), the first analysis of the complex interaction 94 
between patient demographics and tumour subtype, to more accurately estimate the risk of SARS-CoV-2 infection 95 
/ COVID-19 in patients with cancer. We describe the clinical outcomes of COVID-19+ cancer patients entered on 96 
the UKCCMP registry, and compare primary cancer subtype prevalence/case fatality rate to the United Kingdom’s 97 





Study Design and Participants 101 
The UKCCMP database of United Kingdom (UK) cancer patients was set up on the 18th of March and has been 102 
designed as a Public Health Surveillance registry for the COVID-19 pandemic. At an institutional level, the entry of 103 
patients on to the registry was approved according to local information governance processes. All patients with 104 
active cancer and who presented to a cancer centre within the UKCCMP network from March 18th 2020 with a 105 
positive SARS-CoV-2 test, were eligible for enrolment on the registry. The patients presented for secondary care 106 
review for potential hospitalization and were not part of a proactive surveillance program. Patients with active 107 
cancer were defined as those with metastatic cancer, or those undergoing anti-cancer treatment in any setting 108 
(curative/radical/adjuvant/neoadjuvant) or those treated within the past 12 months with surgery/cytotoxic 109 
chemotherapy/radiotherapy. Data collection is ongoing within the registry but for all patients presented here, 110 
outcomes were monitored up to May 8th 2020. This study was conducted in accordance with the Strengthening the 111 
Reporting of Observational studies in Epidemiology (STROBE) statement. 112 
 113 
 114 
Data Collection  115 
Prospective data collection was performed by a pan-UK cancer centre emergency response network set up by the 116 
UKCCMP. All registry patient entries were de-identified at source to ensure that all data is anonymous to 117 
researchers. Data was entered into a Research Electronic Data Capture (REDCap) browser-based metadata 118 
driven electronic data capture (EDC) software system. (10) The secure EDC platform was hosted by the Institute 119 
of Translational Medicine at the University of Birmingham. Patient demographics and cancer features were 120 
obtained from the direct assessment of the Emergency Response Reporting Individual or Local Emergency 121 
Response Reporting Group (ERRI/LERRG) and/or through hospital medical records. In keeping with international 122 
practice, patients were deemed to have SARS-CoV-2 infection if there was a positive Real-Time Reverse 123 
Transcription Polymerase Chain Reaction (RT-PCR) assay test from a throat/nose swab. Patients with a 124 
radiological, clinical diagnosis of SARS-CoV-2, without a positive RT-PCR test were not included in this analysis. 125 
Bronchoalveolar lavage is not recommended in the UK (27). Primary cancer subtype was defined according to 126 
ICD-10 diagnostic codes.  127 
 128 
Clinical management 129 
Management of cancer patients with COVID-19 was directed by the patient’s clinician team without input from the 130 
UK CCMP. They were based on local policies and standard UK clinical practice at the time of this study. Decisions 131 
on ITU admission and ventilation were guided by the UK National Health Service, National Institute of Health and 132 
Care Excellence COVID-19 rapid guidelines (11).   133 
 134 
UKCCMP data processing and analysis 135 
The data through the REDCap platform was transferred securely through to the Compute and Storage for Life 136 
Science (CaStLeS) infrastructure as part of the Birmingham Environment for Academic Research local Cloud 137 
(BEARCloud) (12) via the Centre for Computational Biology, University of Birmingham. Within CaStLeS, the data 138 
is curated to avoid duplications and errors, then annotated with further information such as geolocation before it 139 
can be analysed and disseminated.  140 
 141 
Comparator data sources 142 
A historical control dataset was obtained from the UK Office for National Statistics (ONS). Tumour subtype and 143 
demographics analysis utilised the latest release of the “Cancer Registration Statistics, England, 2017” which is 144 
publicly available. (13). This is the latest cancer registration database in England and involves registrations of 145 
patients up to 2017. Cancer registrations in England take years after a given calendar year to reach nationally 146 
validated quality control measures for robustness of analyses due to continuing accrual of registrations.  147 
 148 
Statistical analysis & Data visualisation 149 
In this study, we report on the cancer patient demographics (primary tumour subtype, age and gender) of those 150 
who contract the SARS-CoV-2 infection and describe their COVID-19 clinical course. We compare these 151 
demographic characteristics with those gleaned for the whole cancer population from the UK Office for National 152 
Statistics (ONS) cancer control dataset. The primary outcome of interest was all-cause inpatient case fatality rate 153 
(during the COVID-19 episode) and this was used for all regression analyses and analyses by tumour subtype. 154 
This included death designated as a direct result of COVID-19 as well as death from any other cause such as 155 
cancer progression and treatment toxicity. Skin cancers were not included in these analyses as they are excluded 156 
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from the ONS dataset. Patients with an unspecified tumour subtype were also excluded from this analysis. A two-157 
sided Fisher’s exact test was used to compare categorical data from different categories. Multivariable logistic 158 
regression (14) was used to estimate odd ratios and 95% confidence intervals of each defined factor after 159 





Susceptibility to SARS-CoV-2 Infection 163 
We are reporting on 1,044 patients with active cancer and a documented SARS-CoV-2 infection/COVID-19 164 
registered in the UKCCMP database with outcomes censored at 8th May, 2020. Of this cohort, 595 were men 165 
(57.0%) and the median age was 70 years, IQR 60-77. Patients were followed up from the point of COVID-19 166 
diagnosis to either discharge from hospital or death. Mean follow up was 7.8 days (standard deviation 8.2 days). 167 
 168 
The demographics and cancer subtype of the COVID-19+ cancer population from the UKCCMP registry were 169 
compared with those from the population of cancer patients represented in the ONS cancer census which was 170 
used as a historical control group. Compared to the ONS control population of cancer patients, we found that 171 
COVID-19+ cancer patients were significantly more likely to be male (57.0% in UKCCMP vs 51.3% in ONS, OR 172 
1.26 95% CI [1.12 to 1.43]; p=0.0002) but the age distribution of cancer patients who contracted COVID-19 was 173 
not significantly different to the ONS cancer control population (median age group 70-79 for both series) (Supp. 174 
Figure 1).  175 
 176 
We found that certain tumour subtypes were overrepresented in the UKCCMP COVID-19+ patient cohort. Patients 177 
with haematological malignancies appeared to be at significantly increased risk, and these included those with 178 
leukaemia (OR 2.82 95% CI [2.21 to 3.55]; p<0.001), myeloma (OR 2.03 95% CI [1.42 to 2.83]; p<0.001) and 179 
lymphomas (OR 1.63 95% CI [1.28 to 2.06]; p<0.001) (Table 1). In contrast, patients with lung cancer and prostate 180 
cancer were relatively underrepresented in the COVID19+ UKCCMP series compared to the control ONS series 181 
of cancers. Lung cancer made up 10.7% of the UKCCMP series compared to 13.7% of ONS cases (OR 0.75 182 
95%CI [0.61-0.91]; p=0.003). Similarly, prostate cancer comprised 11.0% of the UKCCMP series compared to 183 
14.6% of the ONS cohort (OR 0.72 95%CI [0.59-0.88]; p<0.001). 184 
 185 
Case fatality rate from COVID-19  186 
337 of the 1044 COVID-19+ UKCCMP cancer patients died (29.7%), of which the cause of death was recorded as 187 
due to COVID-19 in 92.3% (n=311). The all-cause case fatality rate in cancer patients following COVID-19 was 188 
significantly linked to increasing age, with the case fatality rate in the 40-49, 50-59, 60-69, 70-79 and over 80 189 
groups being 0.10, 0.17, 0.28, 0.35 and 0.48 respectively, and no deaths recorded in the under 40 group (Figure 190 
1, Supp. Figure 2). In addition, the all-cause case fatality rate in cancer patients once they had contracted COVID-191 
19 also appeared to be associated with gender, in males being 0.34 and that in females being 0.23, (OR 1.92 95% 192 
CI [1.51 to 2.45], p<0.001). We confirmed that advancing age was a significant risk factor for death following 193 
COVID-19, with the population of over 70-year olds being over-represented (Supp. Figure 3).   194 
 195 
We compared the case fatality rate for each primary tumour subtype in the UK CCMP to a reference, the C15-C26 196 
subtype (digestive organs) as it was the tumour subtype with the central case fatality rate. On univariate analysis 197 
we observed a significantly higher risk in patients with prostate cancer (OR 2.14, 95% CI [1.17 to 3.96]; p=0.014), 198 
and leukaemia (OR 2.03, 95% CI [1.04 to 3.97]; p=0.038) and a significantly lower risk for patients with breast 199 
cancer (OR 0.53, 95% CI [0.28 to 1.00]; p=0.049) and female genital organ cancer (OR 0.36, 95% CI [0.13-0.87]; 200 
p=0.031) (Figure 2, Supp. Figure 4). We then performed a multivariate correction for clinically relevant confounders, 201 
age and gender. Compared to the rest of the UKCCMP cohort, patients with leukaemia remained at significantly 202 
increased case fatality rate (OR 2.25, 95% CI [1.13 to 4.57]; p=0.023),  (Table 2, Supp. Figure 5). However, after 203 
multivariate correction, prostate cancer was no longer significantly associated with increased case fatality rate, and 204 
breast and female genital cancers were no longer associated with reduced case fatality rate, highlighting the striking 205 
effect of patient age and gender on case fatality rate. Also, on multivariate analysis, we did not find a significantly 206 
increased case fatality rate from COVID19 in the lung cancer population (OR 1.41 95%CI [0.75-2.67]; p=0.285) 207 
compared to the rest of the UKCCMP population. 208 
 209 
We then undertook a specific detailed analysis of the 227 patients with haematological malignancies who were 210 
diagnosed with COVID-19. Compared to the remainder of the UKCCMP cohort (with non-haematological cancers), 211 
we found that these patients presented with similar symptoms. (Supp Table 2). However, adjusting for potential 212 
confounding variables of age and gender, patients with haematological malignancies were significantly more likely 213 
to require high flow oxygen (OR 1.82 95% CI [1.11 to 2.94]; p =0.015)], non-invasive ventilation (OR 2.10 95% CI 214 
[1.14-3.76; p=0.014]), ITU admission for ventilation (OR 2.73 % CI [1.43 to 5.11]; p=0.002) and have a 215 
severe/critical disease course (OR 1.57 95% CI [1.15 to 2.15]; p=0.004) (Supp. Table 1). 47.6% of patients with 216 
haematological malignancies had received recent chemotherapy within 4 weeks of COVID-19 presentation 217 
compared to 29.5% of those with non-haematological cancers (OR 2.15 95% CI [1.57-2.95]; p<0.0001) (Supp. 218 
Table 1). On univariate analysis, recent use of chemotherapy in these patients, was not associated with significantly 219 
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increased risk compared to those who had no recent chemotherapy use. However, following correction for age and 220 
gender, patients with haematological malignancies who had recent chemotherapy were at increased risk of death 221 





During the COVID-19 pandemic, there has been a dual fold effect on cancer practice. There have been radical 225 
changes to the treatment of patients already diagnosed with cancer, including cessation/interruptions of active 226 
therapies and delays in surgery. (15) (16) There has also been a concerning dramatic reduction in oncology 227 
referrals to secondary care in the United Kingdom. (17) There is likely to have been a number of factors contributing 228 
to this observation. However, a perception of excessive vulnerability of all cancer patients or futility of cancer 229 
treatments in the context of a pandemic is one proposed cause. Unchallenged, this is likely to lead to 230 
decreased/delayed cancer presentations or referrals and expose a significant proportion of the population to 231 
considerable harm beyond COVID-19. At the inception of our study, the largest study of cancer patients who 232 
developed COVID-19 was a 105 patient cohort study from China and the authors reported high mortality rates from 233 
COVID-19 in patients with haematological malignancies, lung cancer and patients with metastatic cancer. (18) 234 
However, the small size of that cohort and therefore the very small numbers of patients with each tumour type 235 
within it, made it difficult to be conclusive about these findings. For all cancer patients, in any situation, whether we 236 
are attempting cure or trying to palliate symptoms and extend life, there is a fine balance between potential benefits 237 
and risks of treatment. Therefore, it is critical that we do properly identify the individualised risk of harm from COVID-238 
19 for each cancer patient, rather than treating them as a homogeneous ‘vulnerable’ population, and that we put 239 
that risk into the context of their individual cancer prognosis.  240 
 241 
Risk of severe morbidity and eventual mortality from SARS-CoV-2 infection for any individual in the population is 242 
driven by two key factors, baseline viral susceptibility and the ensuing COVID-19 phenotype. Viral susceptibility is 243 
a dynamic interplay between specific exposure and potential host predisposition/vulnerability to infection. In cancer 244 
patients, there may be a particular host predisposition/vulnerability either as a result of having a dysregulated 245 
immune response skewing it away from an ability to fight viral infection; or indeed cancer-induced damage to 246 
epithelial membranes. The COVID-19 phenotype experienced by a cancer patient is likely to be a complex interplay 247 
of several factors, including patient demographics, other co-morbidities, cancer phenotype and effects of cancer 248 
treatment, as well as the intensity of COVID-19 treatment that the individual patient then receives. 249 
 250 
The UKCCMP has collected primary tumour type and demographic data on over 1000 patients with cancer who 251 
contracted SARS-CoV-2 and developed COVID-19, and analysed this not only within the UKCCMP population, but 252 
also compared it with ONS data from the general cancer population. This has allowed us to segregate the cancer 253 
population by risk, considering the already known risk factors for COVID-19 such as gender (males at higher risk 254 
than females) and advancing age.  255 
 256 
In this study, we have found that both viral susceptibility and the COVID-19 phenotype are influenced by primary 257 
tumour subtype. Patients with haematological malignancies (leukaemias, lymphomas and myelomas) appear to 258 
have an a priori increased viral susceptibility, and to be at greater risk of having a more severe COVID-19 clinical 259 
phenotype, to require more intensive supportive interventions, and to suffer an elevated risk of death. Patients with 260 
the haematological codes (C86, C88, C96) had the highest viral susceptibility. The reasons for this are unclear and 261 
likely reflects the small number of patients involved and stochastic effects (n=29), but it is possible that these 262 
haematological subtypes may have a specific immunological susceptibility to COVID-19 infection. On multivariate 263 
analysis, patients with leukaemia still had a significantly higher risk of death related to COVID-19, considering age 264 
and gender. The increased case fatality rate in haematological malignancies is similar to that observed in a pre-265 
print article from the United Kingdom (19) and Chinese cohorts (20) (21), but in contrast to a recent American 266 
cohort study (22) which does not suggest increased mortality in this group.  267 
 268 
Recent large COVID-19 cancer cohorts of predominantly solid organ tumours have identified no significant excess 269 
mortality risk from recent chemotherapy (16) (22). In this study, we have identified that in haematological 270 
malignancies, following multivariable analysis, risk does appear to be heightened by recent (within 4 weeks) or 271 
current chemotherapy. It is possible that haematological patients undergoing chemotherapy may be responsible 272 
for observations from other cohorts (23).  273 
 274 
There are likely to be a number of possible reasons for these observations. The immunological disruption per se 275 
observed in patients with leukaemia and the use of intensely myelosuppressive regimes may result in a devastating 276 
combination of risk, both in terms of the likelihood of initial SARS-CoV-2 infection and its ability to gain a foothold 277 
in the host and also in terms of the downstream disease course and likelihood of severe consequences such as 278 
cytokine storm and significant multiorgan failure. Further work is necessary in larger haematological cancer cohorts 279 




Contrary to the findings from the Chinese series and data from a European registry (24), we found that patients 282 
with lung cancer were relatively underrepresented in the UKCCMP cohort compared to the ONS data. In addition, 283 
once COVID-19 was established in lung cancer patients, we found no significantly increased case fatality rate 284 
compared to the general COVID19+ cancer population within UKCCMP, suggesting that lung cancer patients are 285 
not a specifically vulnerable group. There are likely to be a number of reasons for this difference in findings. Firstly, 286 
there are methodological differences, with this study comparing lung cancer cases to a cancer population rather 287 
than a non-cancer population. Secondly, there may now be more effective shielding of lung cancer patients at an 288 
early stage in the pandemic when they were designated as vulnerable. Thirdly, lung cancer is the commonest 289 
cancer in China, and hence would be overrepresented in their COVID-19+ cancer patient population and finally the 290 
European registry does not use a controlled group and this highlights the importance of our intra population-291 
controlled studies.  292 
 293 
Prostate cancer patients were relatively underrepresented in the UKCCMP cohort again compared to ONS data, 294 
again perhaps due to shielding, or perhaps due to a reluctance to bring this cohort of patients to hospital even if 295 
they developed COVID symptoms. In terms of risk of death once COVID-19 was established, initially the prostate 296 
cancer group of patients did appear to be an increased case fatality rate, but multivariate analysis that actually their 297 
risk was no greater than the rest of the COVID-19+ cancer population in UKCCMP, reflecting again the importance 298 
of gender more specifically as factor. 299 
 300 
Patients with breast cancers or malignancies of the female genital tract appeared to be at much lower risk, either 301 
of contracting or of dying from COVID-19. However multivariate analysis again demonstrated that this protection 302 
was by virtue of the patients being female, rather than an inherently lower risk tumour per se. (25) (26) 303 
 304 
Overall, in interpreting these data, and putting them into context, our diverse subpopulations of cancer patients are 305 
at equally diverse risks of SARS-CoV-2 infection and of suffering a severe COVID-19 phenotype upon infection. 306 
This needs to be borne in mind when deciding on the level of shielding cancer patients require, depending on the 307 
likely prognosis from their cancer. For example, many patients may take the risk of COVID-19 and see their 308 
grandchildren, rather than spend the last two months of their life alone. Exposure to SARS-CoV-2 should be 309 
minimised for all cancer patients through judicious and contextualised use of social/clinical isolation measures but 310 
also perhaps through measures such as regular SARS-CoV-2 infection screening of their clinical and home 311 
contacts whilst continuing treatment with optimal anti-cancer treatment. However, enhanced strategies to prevent 312 
viral transmission must be employed in patients with haematological conditions, particularly where the risk of not 313 
proceeding with systemic treatment is high. For all cancer types, risk is lower in younger patients and those of 314 
female sex, reinforcing the importance of gender and age as determinants of SARS-CoV-2 / COVID-19 risk. 315 
 316 
This paper allows oncologists and other healthcare professionals to more effectively risk stratify cancer patients 317 
and to counsel them accordingly during this unprecedented time for oncological care. We note some of the 318 
limitations of this analysis. Our analyses are based on symptomatic cancer patients who seek help from cancer 319 
centres. Therefore, the cohort may not be entirely representative of all patients with cancer, and patients may 320 
therefore be more likely to be those under ongoing oncological follow-up, and less likely to be patients on an end 321 
of life pathway or from nursing homes/hospices. There may be limitations in our comparison to the ONS control 322 
population of cancer patients. In this study, we report on patients with “Active Cancer” whereas the ONS control 323 
population is a historical control, consisting of all patients with a diagnosis of cancer up to 2017 and therapies in 324 
oncology and the spectrum of disease may have changed. Therefore, more contemporary analyses, in diverse 325 
population datasets will need to be performed. In addition, as discussed, there is a low admission rate of cancer 326 
patients to ITU, which is likely to impact on COVID-19 outcomes in cancer patients in the United Kingdom (16). 327 
Furthermore, we have only performed multivariable correction for age and sex, which appear to be the primary 328 
drivers of case fatality. Finally, this analysis has been performed without an a priori power calculation in order to 329 
facilitate timely dissemination of results.  330 
 331 
However, rates of COVID-19 in cancer patients remain thankfully low overall and the age distribution of patients in 332 
the UKCCMP reflects the age distribution in the ONS dataset suggesting that our comparator population is as 333 
appropriate as possible at this stage.  334 
 335 
Despite these noted limitations, our study is unique in comparing the dataset to an accurate cancer population 336 
control dataset. Morbidity and case fatality rate from COVID-19 (once established) in UK cancer patients attending 337 
hospital is relatively high, particularly in those with haematological malignancies and advancing age, but not all 338 
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cancer patients are affected equally which is a very important finding. The UKCCMP will continue to monitor risks 339 
to patients following the end of the first UK pandemic peak, provide early warning of further pandemic peaks and 340 
provide timely and meaningful information to the cancer community to enable the highest quality of cancer care to 341 
continue.  342 
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  UKCCMP cases (%) ONS cases (%) Odds Ratio (95% CI) p value 
Patient Features         
-Male 595 (57.0%) 145034 (51.3%) 1.26 (1.12-1.43) 0.0002 
-Female 445 (42.6%) 137844 (48.7%)     
-Other 4 (0.4%) 0 (0.0%)     
-Median age/years 70 NA*     
Cancer Subtype         
-Breast (C50-C50) 143 (13.7%) 46109 (16.3%) 0.82 (0.68-0.98) 0.026 
-Colorectal (C18-C21) 124 (11.9%) 36039 (12.7%) 0.93 (0.76-1.12) 0.456 
-Prostate (C61) 114 (11.0%) 41200 (14.6%) 0.72 (0.59-0.88) <0.001 
-Lung (C34) 111 (10.7%) 38878 (13.7%) 0.75 (0.61-0.91) 0.003 
-Digestive organs (non-colorectal) (C15-C26) 95 (9.1%) 30096 (10.6%) 0.84 (0.68-1.04) 0.118 
-Urinary tract (C64-C68) 77 (7.4%) 19333 (6.8%) 1.09 (0.85-1.38) 0.46 
-Female genital organs (C51-C58) 56 (5.4%) 17969 (6.4%) 0.84 (0.63-1.10) 0.226 
-Lip, oral cavity and pharynx (C00-C14) 33 (3.2%) 7558 (2.7%) 1.19 (0.82-1.69) 0.334 
-Central nervous system (C69-C72) 25 (2.4%) 5038 (1.8%) 1.36 (0.87-2.02) 0.127 
-Mesothelial and soft tissue (C45-C49) 16 (1.5%) 4682 (1.7%) 0.93 (0.53-1.52) 0.903 
-Respiratory and intrathoracic organs (not lung) (C30-C39) 11 (1.1%) 2780 (1.0%) 1.08 (0.53-1.94) 0.752 
-Bone and articular cartilage (C40-C41) 4 (0.4%) 376 (0.1%) 2.90 (0.78-7.50) 0.053 
-Male genital organs (C60-C63) 4 (0.4%) 2435 (0.9%) 0.44 (0.12-1.14) 0.126 
-Endocrine glands (C73-C75) 4 (0.4%) 3374 (1.2%) 0.32 (0.09-0.82) 0.01 
-Lymphoma (C81-C85) 79 (7.6%) 13537 (4.8%) 1.63 (1.28-2.06) <0.001 
-Leukaemia (C91-C95) 79 (7.6%) 8018 (2.8%) 2.82 (2.21-3.55) <0.001 
-Myeloma (C90) 37 (3.6%) 5033 (1.8%) 2.03 (1.42-2.83) <0.001 
-Other Haematological (C86, C88, C96) 29 (2.8%) 423 (0.1%) 19.14 (12.59-28.05) <0.001 
Table 1: Demographics and tumour subtype representation in the UKCCMP Covid-19 cohort compared to the ONS cancer control 343 
population. * Individual ages not available in dataset. Univariate analysis was performed, p values were determined by Fisher exact test 344 
and unadjusted for age and gender.  345 









ratio (95% CI) p value  
Multivariable 
adjusted odds 
ratio (95% CI) p value 
Prostate (C61) 49 0.43 2.14 (1.17-3.96) 0.014 1.09 (0.51-2.33) 0.824 
Lung (C34) 43 0.387 1.62 (0.89-3.00) 0.118 1.41 (0.75-2.67) 0.285 
Mesothelial and soft tissue (C45-C49) 6 0.375 1.18 (0.37-3.51) 0.772 1.52 (0.43-5.30) 0.505 
Urinary tract (C64-C68) 23 0.299 1.08 (0.54-2.13) 0.834 0.87 (0.41-1.81) 0.715 
Colorectal (C18-C21) 35 0.282 1.03 (0.56-1.90) 0.934 0.85 (0.44-1.64) 0.627 
Central nervous system (C69-C72) 7 0.28 1.15 (0.39-3.18) 0.797 1.87 (0.57-6.05) 0.292 
Respiratory organs (C30-C39) 3 0.273 0.84 (0.17-3.29) 0.813 0.96 (0.18-4.10) 0.954 
Lip, oral cavity and pharynx (C00-C14) 8 0.242 0.75 (0.28-1.85) 0.542 0.77 (0.25-2.27) 0.644 
Breast (C50) 26 0.182 0.53 (0.28-1.00) 0.049 0.97 (0.40-2.52) 0.942 
Female genital organs (C51-C58) 7 0.125 0.36 (0.13-0.87) 0.031 0.79 (0.24-2.63) 0.704 
Myeloma (C90) 16 0.432 1.85 (0.81-4.22) 0.142 1.65 (0.71-3.85) 0.241 
Leukaemia (C91-C95) 33 0.418 2.03 (1.04-3.97) 0.038 2.25 (1.13-4.57) 0.023 
Lymphoma (C81-C85) 25 0.316 1.60 (0.80-3.19) 0.184 1.72 (0.81-3.68) 0.156 
Other Haematological (C86, C88, C96) 7 0.241 0.81 (0.28-2.12) 0.675 0.81 (0.26-2.33) 0.702 
Digestive organs (C15-C17, C22-C26) 28 0.295 Reference Reference Reference Reference 
 347 
Table 2: All-cause case fatality rate following COVID-19 by tumour subtype, before and after age and sex correction. Odds ratio was 348 
performed relative to Digestive organs (non-colorectal) (C15-C26). Multivariable corrections were performed correcting for patient age 349 











Figure 2: Heatmap demonstrating case fatality rate following a COVID-19 presentation, broken down by tumour subtype, age and 359 
gender. Grey bars represent where number of cases were less than 4.  360 
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SUPPLEMENTARY METHODS 361 
 362 
Statistical analysis & Data visualisation 363 
Analyses were performed in R version 3.6.3 utilising the glm() (family = binomial(link = "logit")) and fisher.test() 364 
functions, respectively. Data processing and visualisation utilised R (version 3.6.3) packages including broom, 365 
dplyr, forestplot, ggplot2, ggsci, pheatmap, RColorBrewer, robustbase and viridis. Data subsetting was performed 366 
using the subset() function of ‘robustbase’ and data reshaping for visualisation involved the use of the tidy() function 367 
of ‘broom’, and group_by() and melt() functions of ‘dplyr’. Functions from the ggplot2 R package were used to 368 
generate multiple plots including barplots (geom_bar) and lineplots (geom_line). The pheatmap() and forestplot() 369 
functions of the ‘pheatmap’ and ‘forestplot’ R packages was also used to generate the heatmap and forest plots, 370 
respectively. 371 
 372 
Data Collection  373 
Prospective data collection was performed by the pan-UK cancer centre emergency response network. Case 374 
reporting was led by a COVID-19 Emergency Response Reporting Individual (ERRI), supported by a Local 375 
Emergency Response Reporting Group (LERRG) at each centre. The UKCCMP encouraged all local reporting 376 
sites to enter data in a real time basis, as soon as a positive SARS-CoV-2 test had been identified. The data 377 
fields were then re-updated as soon as treatment and outcomes had been identified. The ERRI was a 378 
trained/training oncologist who did data review, annotation and entry. In a small number of centres, data entry 379 
was performed by data managers but with direct oversight by the ERRI. This secure EDC platform is hosted by 380 
the Institute of Translational Medicine at the University of Birmingham.  381 






Supplementary Figure 1. Stacked bar chart showing age distribution of cancer patients in the UKCCMP who had contracted SARS-386 
CoV-2 and ONS cancer control population. 387 
 388 
 389 
Supplementary Figure 2. Forest plot showing distribution of age groups of cancer patients who died in the UKCCMP and case fatality 390 




Supplementary Figure 3: Forest plot showing distribution of age groups of patients who died in the UKCCMP relative to the age 393 
distribution of the ONS cancer control population.  394 
 395 
 396 
     397 
Supplementary Figure 4: Case fatality rate of patients following a presenting with COVID-19 in the UKCCMP cohort, assessed by 398 






Supp Figure 5. Waterfall plot showing risk of death for each tumour subtype following COVID-19 compared to other subtypes 403 
(reference), before and after age and sex correction multivariable correction. * denotes statistical significance of p adjusted, where * 404 











Univariate analysis   Multivariable adjusted analysis 
      Odds Ratio (CI) p value Odds Ratio (CI) p value 
Patient features             
- Male 148 (65.2%) 447 (54.7%) 1.53 (1.13-2.09) 0.006 1.58 (1.16-2.16) 0.004 
- Female 79 (34.8%) 366 (44.8%)         
- Other 0 (0.0%) 4 (0.5%)         
- Median age/years (std) 69 (14.16) 70 (13.09)   0.034     
Co-morbidities             
- Cardiovascular disease 21 (9.3%) 124 (15.2%) 0.56 (0.34-0.91) 0.023 0.62 (0.36-1.01) 0.065 
- COPD 7 (3.1%) 73 (8.9%) 0.32 (0.13-0.66) 0.005 0.35 (0.14-0.72) 0.009 
- Diabetes 33 (14.5%) 145 (17.7%) 0.79 (0.51-1.18) 0.262 0.78 (0.50-1.17) 0.243 
- Hypertension 60 (26.4%) 283 (34.6%) 0.66 (0.47-0.92) 0.017 0.68 (0.47-0.97) 0.033 
- None 52 (22.9%) 153 (18.7%) 1.32 (0.91-1.90) 0.138 1.31 (0.87-1.96) 0.189 
- No data 39 (17.2%) 136 (16.6%)         
Smoking status             
- Current smoker 7 (3.1%) 38 (4.7%) 0.99 (0.39-2.17) 0.984 0.77 (0.30-1.74) 0.558 
- Ex-smoker 32 (14.1%) 234 (28.6%) 0.59 (0.37-0.94) 0.028 0.63 (0.38-1.03) 0.067 
- Never smoker 52 (22.9%) 218 (26.7%) 1.66 (1.06-2.63) 0.027 1.67 (1.04-2.70) 0.035 
- No data 136 (59.9%) 327 (40.0%)         
Patient outcome             
 - Death (all cause) 82 (36.1%) 237 (29.0%) 1.61 (1.15-2.24) 0.005 1.74 (1.21-2.48) 0.002 
 - Death (COVID-19) 80 (35.2%) 215 (26.3%) 1.77 (1.27-2.48) 0.001 1.93 (1.35-2.77) <0.001 
 - Death (Cancer) 1 (0.4%) 18 (2.2%) 0.21 (0.01-1.02) 0.129 0.22 (0.01-1.06) 0.138 
 - Death (other) 1 (0.4%) 4 (0.5%) 0.96 (0.05-6.54) 0.972 1.12 (0.06-7.79) 0.923 
 - Hospitalised 5 (2.2%) 36 (4.4%) 0.52 (0.18-1.23) 0.178 0.53 (0.18-1.26) 0.192 
Cancer treatment within 4 
weeks 
          
- Chemotherapy 108 (47.6%) 241 (29.5%) 2.17 (1.60-2.93) <0.0001 2.15 (1.57-2.95) <0.0001 
- Immunotherapy 0 (0.0%) 39 (4.8%) 0.00 (0.00-2.90E+07) 0.9815 0.00 (0.00-3.17E+07) 0.9813 
- Radiotherapy 2 (0.9%) 84 (10.3%) 0.08 (0.01-0.25) 0.0004 0.07 (0.01-0.24) 0.0003 
- Surgery  0 (0.0%) 36 (4.4%) 0.00 (0.00-8.99E+07) 0.9816 0.00 (0.00-1.39E+08) 0.9816 
- Targeted therapy 26 (11.5%) 65 (8.0%) 1.49 (0.91-2.39) 0.1018 1.45 (0.87-2.33) 0.1397 
COVID-19 Symptoms           
- Chills 9 (4.0%) 23 (2.8%) 1.49 (0.64-3.16) 0.324 1.45 (0.62-3.11) 0.357 
- Corzyal symptoms 13 (5.7%) 47 (5.8%) 1.04 (0.53-1.90) 0.911 1.03 (0.52-1.90) 0.931 
- Cough 93 (41.0%) 381 (46.6%) 0.83 (0.60-1.14) 0.255 0.82 (0.59-1.13) 0.217 
- Diarrhoea 26 (11.5%) 63 (7.7%) 1.63 (0.99-2.62) 0.05 1.67 (1.01-2.70) 0.041 
- Fatigue 46 (20.3%) 150 (18.4%) 1.19 (0.81-1.73) 0.359 1.22 (0.83-1.77) 0.307 
- Fever   133 (58.6%) 450 (55.1%) 1.34 (0.96-1.90) 0.091 1.26 (0.89-1.79) 0.191 
- Headache 15 (6.6%) 28 (3.4%) 2.09 (1.07-3.94) 0.026 2.11 (1.07-4.00) 0.026 
- Myalgia 18 (7.9%) 60 (7.3%) 1.13 (0.64-1.93) 0.654 1.15 (0.64-1.97) 0.623 
- Nausea and/or Vomiting 8 (3.5%) 43 (5.3%) 0.68 (0.29-1.40) 0.332 0.70 (0.30-1.45) 0.372 
- Shortness of breath 84 (37.0%) 324 (39.7%) 0.95 (0.69-1.30) 0.734 0.92 (0.66-1.27) 0.61 
- Sore throat 9 (4.0%) 32 (3.9%) 1.05 (0.47-2.16) 0.891 0.98 (0.43-2.04) 0.964 
- Asymptomatic  5 (2.2%) 39 (4.8%) 0.47 (0.16-1.09) 0.113 0.50 (0.17-1.18) 0.152 
- No data 35 (15.4%) 99 (12.1%)         
COVID-19 Severity Score           
-  severe/critical 119 (52.4%) 339 (41.5%) 1.53 (1.13-2.06) 0.006 1.57 (1.15-2.15) 0.004 
- mild 103 (45.4%) 448 (54.8%)       
- No data 5 (2.2%) 30 (3.7%)         
COVID-19 treatment           
- Antibiotics 145 (63.9%) 495 (60.6%) 1.35 (0.93-2.00) 0.12 1.35 (0.92-2.00) 0.129 
- Fluids 86 (37.9%) 247 (30.2%) 1.52 (1.10-2.11) 0.012 1.54 (1.10-2.14) 0.011 
- High Flow Oxygen (HFO) 29 (12.8%) 61 (7.5%) 1.89 (1.16-3.01) 0.009 1.82 (1.11-2.94) 0.015 
- ITU + Ventilation 19 (8.4%) 25 (3.1%) 3.00 (1.60-5.57) 0.001 2.73 (1.43-5.11) 0.002 
- ITU - Ventilation 7 (3.1%) 12 (1.5%) 2.19 (0.81-5.54) 0.104 2.16 (0.78-5.54) 0.118 
- Non-invasive Ventilation 19 (8.4%) 35 (4.3%) 2.11 (1.16-3.75) 0.012 2.10 (1.14-3.76) 0.014 
- Oxygen 99 (43.6%) 310 (37.9%) 1.38 (1.00-1.90) 0.054 1.41 (1.01-1.96) 0.044 
- None 26 (11.5%) 134 (16.4%) 0.67 (0.42-1.04) 0.083 0.65 (0.41-1.02) 0.071 
- No data 40 (17.6%) 128 (15.7%)         
Supp. Table 1: Univariate and multivariate analyses of differences in patient demographics/symptoms/cancer treatments and clinical 406 
course of haematological vs. non-haematological malignancies. Univariate analysis was conducted with presence compared to absence 407 
(reference for each category) in haematological malignancies vs. non-haematological malignancies. Multivariate analyses were 408 
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